CBP/p300 bromodomain: new promising epigenetic target
Vis Cancer Med, 3 (2022) 3
Published online: 2022-09-12
Articles citing this article
The Citing articles tool gives a list of articles citing the current article.
The citing articles come from EDP Sciences database, as well as other publishers participating in CrossRef Cited-by Linking Program. You can set up your personal account to receive an email alert each time this article is cited by a new article (see the menu on the right-hand side of the abstract page).
Cited article:
This article has been cited by the following article(s):
Discovery of 5-imidazole-3-methylbenz[d]isoxazole derivatives as potent and selective CBP/p300 bromodomain inhibitors for the treatment of acute myeloid leukemia
Jian-kang Hu, Xin Tang, Guo-long Luo, Cheng Zhang, Tian-bang Wu, Chao Wang, Hui Shen, Xiao-fan Zhao, Xi-shan Wu, Jeff B. Smaill, Yong Xu, Yan Zhang and Qiu-ping XiangActa Pharmacologica Sinica 46 (6) 1706 (2025)
https://doi.org/10.1038/s41401-025-01478-x
https://doi.org/10.1039/9781837674916-part3
266 (2024)
https://doi.org/10.1039/9781837674916-00266
Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatment
Magdalena Strachowska and Agnieszka RobaszkiewiczPharmacology & Therapeutics 257 108636 (2024)
https://doi.org/10.1016/j.pharmthera.2024.108636